, however the amount of drug bioavailable to the body is only about 20-30 % because of extensive hepatic fi rst-pass metabolism. After oral and intravenous dosing, pentoxifylline is extensively metabolized. One of the major metabolites in plasma is l-(S'-hydroxyhexyl) 3,7-dimethylxamhine, while the 2 major urinary metabolites are 1-carboxypropyl-7-dimethylxanthine and 1-carboxybutyl-3,7-dimethylxanthine. Pentoxifylline has a short half-life of approximately 1-2 h [ 1 , 4 -7 ] . PTX is not known to induce its own metabolism after multiple oral doses of the drug. Other recognized metabolites have lower plasma concentrations and less or no activity [ 1 ] . Pentoxiphylline excretion is almost totally urinary and no parent drug is essentially found in urine. Small amount (4 %) of the administered dose is recovered in feces. Food intake shortly before dosing delays absorption of an immediate-release dosage form but does not aff ect total absorption. However in the case of PTX sustained release tablets the total extent of absorption is also increased by co-administration of drug with meals. -6493-05-6) is a xanthine derivative useful in intermittent claudication on the basis of chronic occlusive arterial disease of the limbs [ 1 ] . Intermittent claudication (IC) is defi ned by leg muscle pain, cramping and fatigue brought on by ambulation/exercise; relieved on rest; and caused by inadequate blood supply and is the primary symptom of peripheral arterial disease (PAD) [ 2 ] . It can improve function and symptoms but is not intended to replace more defi nitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease [ 3 ] . The mechanism by which pentoxifylline (PTX) works is not well known, but appears to be related to erythrocyte adenosine triphosphate (ATP) concentrations and the phosphorylation of erythrocyte membrane proteins, both mechanisms resulting in an improvement in erythrocyte fl exibility [ 2 ] . PTX is a highly water-soluble drug (~ 77 mg/mL) and is well absorbed from the gastrointestinal tract 
Introduction

▼
Pentoxifylline [1-(5-oxohcxyl)-3,7-dimethylxanthine] (CAS-6493-05-6) is a xanthine derivative useful in intermittent claudication on the basis of chronic occlusive arterial disease of the limbs [ 1 ] . Intermittent claudication (IC) is defi ned by leg muscle pain, cramping and fatigue brought on by ambulation/exercise; relieved on rest; and caused by inadequate blood supply and is the primary symptom of peripheral arterial disease (PAD) [ 2 ] . It can improve function and symptoms but is not intended to replace more defi nitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease [ 3 ] . The mechanism by which pentoxifylline (PTX) works is not well known, but appears to be related to erythrocyte adenosine triphosphate (ATP) concentrations and the phosphorylation of erythrocyte membrane proteins, both mechanisms resulting in an improvement in erythrocyte fl exibility [ 2 ] . PTX is a highly water-soluble drug (~ 77 mg/mL) and is well absorbed from the gastrointestinal tract ▼ Pentoxifylline is a xanthine derivative that is indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. In the present study, prior to the in vivo study, an in vitro comparative dissolution test was performed by the paddle method for 2 oral sustained release pentoxifylline tablets (400 mg) following the bioequivalence guidance of FDA. Metrics of peak exposure (C max ) and total exposure to 24 h (AUC 24 ) were compared using a randomized, single oral, open-label, 2-period, 2-sequence, 2 treatments crossover study in 24 healthy male volunteers under fasted conditions. After an overnight fast, the volunteers received 400 mg pentoxifylline and the blood samples were collected over a 24-h period following drug administration. Plasma drug concentrations were measured by a reverse-phase HPLC method with ultraviolet detection. In vitro dissolution tests requirements were met by both formulations. Observed exposure metrics for test and reference products were 140.6 ± 51.5 and 132.6 ± 48.5 ng/ml for C max and 986.4 ± 350.7and 1 035.8 ± 350.3 ng.h/ml for AUC 0-24 respectively. The confi dence intervals (90 %) around ratios (test/reference) of least squares means derived from logarithmic transformed exposure metrics were 0.9912-1.1564 % for C max and 0.8886-1.0535 % for AUC 0-24 . Therefore it can be concluded that both products are bioequivalent in terms of peak and total exposure and therefore interchangeable.
Pentoxiphylline is made and marketed by more than one pharmaceutical manufacturer. There is evidence that the bioavailability of diff erent formulations of the same drug, in the same dosage form and the same strength may be diff erent which could be a special challenge to physicians and pharmacists regarding the therapeutic eff ect of the products. For this purpose the bioavailability of drug products are determined and compared according to FDA guidelines. The objective of this study was to assess the in vitro and in vivo bioequivalence of generic pentoxifylline preparations at 400 mg after a single oral dose administration in healthy Iranian male volunteers.
Methods
▼
Dissolution testing
Dissolution studies on test and reference sustained release tablets of PTX were conducted in USP apparatus 2 (paddle method) with 12 replicates. The dissolution medium was 900 mL water. The paddle rotation speed was kept at 75 rpm. Samples were withdrawn and fi ltered at 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 h, and assayed by UV spectrophotometry at 274 nm (Shimadzu UV-160A, Japan). Cumulative percentages of the drug dissolved from the tablets were calculated. In vitro bioequivalence was demonstrated by comparison of the dissolution profi le after fi tting into the mathematical model, similarity factor, f 2 . The similarity factor (f 2 ) was calculated to compare the dissolution profi les of a pair of sustained release PTX tablet formulations using the following formula.
Where, f 2 is the similarity factor; n is the number of time points; R t is the mean percent drug dissolved e. g. a reference product; T t is the mean percent drug dissolved of e. g. a test product. An f 2 value between 50 and 100 suggests that the 2 dissolution profi les are similar. The uniformity of dosage units was demonstrated by 2 methods; weight variation and content uniformity, according to the drug monograph in USP30. Finally the assay of drug content which is a global requirement was analyzed for both products using the method described in USP30.
Subjects
24 Iranian healthy male volunteers were enrolled in this study. All of them aged between 20 and 29 years (23.6 ± 2.1 years) and weight from 62 to 100 kg (75.1 ± 10.7 kg). Volunteers were studied for hypersensitivity to pentoxifylline, alcohol dependency or drug addiction, smoking, treatment with other drugs during the last 2 weeks and undergoing a medical examination at another hospital during the study. Before the studies subjects underwent physical examination such as status of the heart, lungs and blood circulation, as well as medical history was recorded. The volunteers were informed about aims, methods, objectives and potential hazards of the study, and written consent was obtained. 
Study design
400 mg PTX as a single sustained release dosage form of the test (Exir Pharmaceutical Co, Boroujerd, Iran) and reference (batch no. 025560) products were randomized and administered to the volunteers after 10 h of overnight fasting in an open label, randomized, 2 sequence, 2 period, crossover study with a 2 week washout period between 2 treatments. A crossover study is a longitudinal study in which subjects receive a sequence of exposures. In crossover studies the infl uence of confounding covariates is reduced because each patient serves as his or her own control. Subjects were given standard breakfast 2 h, lunch 6 h and dinner 12 h after the morning drug administration and were only allowed drinking mineral water during the day getting sample. Serial blood samples from subject's forearm veins were drawn prior to the dosing at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 h after each administration. All samples were centrifuged in heparinized tube. The plasma samples were separated and kept frozen at − 20 °C for subsequent analysis. Each tube was properly labeled indicating patient identity and the sampling time after drug administration.
Analysis of plasma samples
Several extraction procedures have been described for the assay of PTX and its metabolites in biological fl uids [ 8 -11 ] . PTX and its metabolites have been assayed in biological fl uids by thin-layer chromatography (TLC) [ 4 ] , high performance thin-layer chromatography [ 10 , 11 ] , gas chromatography (GC) [ 4 , 12 ] , rapid highperformance liquid chromatography-tandem mass spectrometry [ 9 ] , and several high performance liquid chromatography (HPLC) [ 1 , 4 , 10 , 13 , 14 ] . In this study pentoxifylline plasma concentrations was determined using a modifi ed extraction procedure followed by a high performance liquid chromatographic (HPLC) method which was validated for specifi city, accuracy, precision and sensitivity. Runs contained quality control samples (QC) at 4 concentration levels. The recoveries of PTX analysis at calibration curve concentration range were evaluated by comparison of peak areas obtained after extraction of known amount of drug from plasma with those of obtained from the same amounts of unextracted PTX in water. For sample preparation, on 1 ml of plasma 50 μl of the internal standard (10 μg/ml of theophylline) (Sigma, St Louis, MO, USA) was added, then all samples were extracted with 5 ml diethyl ether (Merck, Darmstadt, Germany) by vortexing for 5 min. Extraction with diethyl ether gave better recovery and cleaner chromatograms with lesser number of peaks. After centrifugation for 5 min at 1 000 g, the upper organic phase was transferred to a 7 ml glass evaporation tube. The tubes were placed in a 45 °C water bath. After dryness the residue reconstituted with 200 μL of the mobile phase by vortex mixing for 20 s. 150 μL of the resulting solution was injected onto the HPLC column. The mobile phase consisted of methanol-tetrahydrofurane-0.02 M monobasic potassium phosphate (Merck, Darmstadt, Germany) pH 4.0 adjusted with o-phosphoric acid (45:1:55, v/v) (Merck, Darmstadt, Germany), Analytical column used for chromatographic separations was Shimpack CLC C18 (250 × 4.6 mm) 5 μm (Shimadzu, Columbia, MD, USA) with a Shimpack C18 (10 × 4 mm) 5 μm precolumn guard (Shimadzu, Columbia, MD, USA); the fl ow rate was 1.5 ml/min; the detector wavelength was set at 273 nm. Under these conditions the retention times for pentoxifylline and the internal standard (theophylline) were 6 and 4 min respectively. A liquid chromatographic system (Beckman, Fullerton, CA, USA) comprising of 126 gold solvent delivery module equipped with a Rheodyne (Rheodyne, Cotati, CA, USA) injector and a variable wavelength ultraviolet spectrophotometric detector (166 gold, Beckman, CA, USA) set at 273 nm. System Gold software was used for data acquisition and System Gold nouveau software was used for data reporting and analysis. 
Pharmacokinetic study
To calculate pharmacokinetic parameters for pentoxifylline the individual plasma concentration-time profi le was constructed using standard non-compartmental methods for each treatment. Maximum plasma concentration (C max ) and the time at which this occurred (T max ) obtained from the individual subject plasma concentration-time profi les. The area under the plasma concentration-time curve from time zero to t (AUC 0-t ) was calculated using the linear trapezoidal rule. The terminal fi rst order constant (k el ) was determined by a least squares fi t of the terminal plasma concentrations (using Excel ® for Windows ® ). The elemination half life (t 1/2 ) was determined with the quotient of 0.693/k el . The constant k el was used to extrapolate AUC t-∞ . AUC 0-∞ was obtained from AUC 0-t plus AUC t-∞ . Bioequivalence between the formulations was determined by calculating 90 % confi dence intervals (90 % C.I.) for the ratio of C max , AUC 0-t , and AUC 0-∞ values for the test and reference products and were compared to the reference intervals (0.8-1.25) as suggested by the FDA [ 15 , 16 ] . Treatments were compared by analysis of variance (ANOVA) with eff ects for sequence, subject nested within sequence, period and treatment. Moreover a computer program (kinetica 5.0 PK/PD Analysis) was used for pharmacokinetic analyses. Peroral data from each volunteer were fi tted to 1, 2 and 3 compartment models with fi rst order absorption, with lag time and elimination from the central compartment.
Results and Discussion
▼
An oral dosage form is normally composed of a drug substance and excipients. The type of excipients, proportion between ingredients, and the manufacturing method of the fi nal product gives each product certain dissolution characteristics, which varies from one brand to the other. According the obtained results both PTX sustained release formulations met the general pharmaceutical specifi cations for weight variation, content assay and content uniformity test. Both products released not more than 30 % in fi rst hour and not less than 80 % within 20 h and passed the USP standard for dissolution test of PTX sustained release tablets. Therefore the obtained results preclude any possibility of problems in bioavailability resulting from drug dissolution and consider the test product interchangeable with the innovator brand. The release profi le of PTX from 2 products is shown in • ▶ Fig. 1 . Moreover for 2 dissolution profi les to be considered similar and bioequivalent, f 2 value should be between 50 and 100, therefore having similarity factor of 51, 2 tested brands are similar and interchangeable. Typical chromatogram of blank human plasma, blank human plasma spiked with theophylline as internal standard, and 5 standard concentrations of pentoxifylline are shown in • ▶ Fig. 2 . All chromatograms are free from any interfering peak at the retention times of PTX and internal standard, theophylline. The LOQ for pentoxifylline was 10 ng/ml and the assay was linear over the concentration ranges 12.5-400 ng/ml, with a coeffi cient of correlation (r 2 ) of 0.999 [ 17 -19 ] , within-day reproducibility of ± 4.46 % for 100 ng/ml and a day-to-day reproducibility of ± 5.55 % for the same concentration. The recovery of pentoxifylline was 82.08, 84.53, and 80.50 % at concentrations of 20, 200, and 400 ng/ml respectively. Recovery of the internal standard was 87 %. The drug was well tolerated by all subjects and no adverse eff ects were reported which could have infl uenced the outcome of the study. The mean serum concentration-time profi les after single oral dose administration of reference and test products are illustrated in the following • ▶ Fig. 3 .
A one-compartment model best described the decline in PTX plasma concentrations following oral administration in each subject. Table 1 . Mean maximum serum concentrations of 140.6 ± 51.5 ng/ml (90 % CI: 123.3-157.9) and 132.6 ± 48.5 ng/ml (90 % CI: 117.4-149.9) were obtained for the test and reference products, respectively. T max , the time required to reach the maximum serum concentration, was 2.21 ± 1.22 h (90 % CI: 1.8-2.62) and 2.77 ± 0.69 h (90 % CI: 2.54-3.00), respectively. Bioavailability parameters are in good agreement with the previous study by Yuen et al. where a generic preparation of PTX sustained release tablet was evaluated in comparison with a proprietary product, Trental 400 [ 20 ] . In that study, the PTX mean ± SD values for C max , T max and AUC 0-∞ were 166.91 ± 69.43 ng/ml, 2.4 ± 0.8 h and 1 078.19 ± 502.14 ng.h/ml for the reference and 181.69 ± 69.92 ng/ml, 2.3 ± 0.7 h and 973.12 ± 423.87 ng.h/ml for the test preparations. In addition to C max and T max , the ratio of C max / AUC 0-∞ also can be used as a parameter for evaluating the absorption rates in bioequivalence studies. These calculated ratios were 14.2 % and 12.9 % for the test and reference products. Table   2 reveal that these values are entirely within the bioequivalence acceptable bounds of 80-125 % for the primary pharmacokinetic parameters proposed by the FDA and EMEA [ 21 , 22 ] . All statistical tests used a 5 % level of signifi cance. The multivariate analysis accomplished through analysis of variance (ANOVA) indicated that there were no statistical diff erences between the 2 formulations with any of the pharmacokinetic parameters ( • ▶ Table 2 ).
Furthermore, periods and sequence eff ects did not infl uence the outcome of the statistical analysis.
Conclusion
▼
The results of in vitro tests confi rm the presence of bioequivalence between the analyzed drugs, which could be a proof of the scientifi c basis for excipient and manufacturing process selection in the development of PTX test product. On the other hand, the currently accepted criterion for bioequivalence for most dosage forms requires that the mean pharmacokinetic parameters of the test dosage form should be within 80-120 % of the reference dosage form using the 90 % confi dence interval. The multivariate analysis, accomplished through analysis of variance (ANOVA) for assessment of period, group and product eff ects, revealed the absence of any of these eff ects in the present study. 
